Pacira Biosciences Inc Call to Discuss that the FDA has Approved its Supplemental New Drug Application Seeking Expansion of the EXPAREL Label Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Pacira Biosciences investor call. (Operator Instructions) I would now like to introduce your host for today's conference call, Ms. Susan Mesco, Head of Investor Relations. You may begin.
Thank you, Kevin, and good morning, everyone. Welcome to today's conference call to discuss the approval of our supplemental new drug application to expand the use of EXPAREL to pediatric patients over 6 years of age. Joining me on today's call is Dave Stack, Chairman and Chief Executive Officer. Additional members of the Pacira executive leadership team are also available for today's question-and-answer session.
Before we begin, let me remind you that today's call will include forward-looking statements based on current expectations. Such statements represent our judgment as of today and may involve risks and uncertainties. For information concerning risk factors that could affect the company, please refer to the company's filings with the SEC which
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
